Setmelanotide Caused Significant Weight Loss in People With Rare Genetic Obesity From POMC or LEPR Deficiency
In phase 3 trials, the MC4R agonist peptide setmelanotide achieved at least 10% weight loss in 80% of POMC-deficient and 45% of LEPR-deficient patients, while dramatically reducing hunger scores.
Quick Facts
What This Study Found
In the POMC deficiency trial (n=10): 80% of participants achieved at least 10% weight loss at approximately 1 year. Mean hunger score reduction was -27.1% (p=0.0005).
In the LEPR deficiency trial (n=11): 45% of participants achieved at least 10% weight loss. Mean hunger score reduction was -43.7% (p<0.0001).
During the placebo-controlled withdrawal phase, symptoms returned when patients were switched to placebo, confirming the drug's direct effect. Most common adverse events were injection site reactions and hyperpigmentation (skin darkening). No serious treatment-related adverse events occurred in either trial.
Key Numbers
How They Did This
Two single-arm, open-label, multicentre phase 3 trials conducted across 10 hospitals in the US, Canada, and Europe. Patients aged 6+ with confirmed POMC or LEPR deficiency received setmelanotide for 12 weeks. Those with meaningful weight loss entered an 8-week blinded withdrawal (4 weeks drug, 4 weeks placebo), then 32 weeks more of open-label treatment. Primary endpoint: proportion achieving ≥10% weight loss at ~1 year.
Why This Research Matters
Before setmelanotide, people with POMC or LEPR deficiency had no treatment that addressed the root cause of their obesity — a broken melanocortin signaling pathway. These patients experience relentless, overwhelming hunger that no amount of willpower can overcome. Setmelanotide directly activates the downstream receptor, restoring appetite control. This represents one of the clearest examples of precision medicine in obesity treatment.
The Bigger Picture
Setmelanotide (brand name IMCIVREE) was approved by the FDA in 2020 based on these trials, becoming the first targeted therapy for genetic obesity. It validated the concept that activating MC4R can treat obesity caused by upstream pathway defects. This has broader implications: researchers are now exploring whether MC4R agonists could help in more common forms of obesity, though the dramatic results seen here may be specific to patients with clear genetic deficiencies.
What This Study Doesn't Tell Us
Very small sample sizes (10 and 11 patients) — inherent to studying extremely rare genetic conditions. The trials were open-label for most of their duration, which could bias weight and hunger assessments. The blinded withdrawal phase was only 8 weeks. Long-term safety data beyond ~1 year was not reported. Skin hyperpigmentation occurred in all POMC patients, reflecting the melanocortin pathway's role in pigmentation.
Questions This Raises
- ?Could setmelanotide or similar MC4R agonists be effective in more common forms of obesity involving partial melanocortin pathway dysfunction?
- ?What is the long-term safety profile of chronic MC4R activation, particularly regarding skin pigmentation and cardiovascular effects?
- ?Are there other rare genetic obesity syndromes that could benefit from MC4R agonist therapy?
Trust & Context
- Key Stat:
- 80% achieved ≥10% weight loss (POMC trial) In patients with lifelong severe genetic obesity who had no previous effective treatment, setmelanotide produced clinically meaningful weight loss and dramatically reduced hunger
- Evidence Grade:
- Phase 3 clinical trials published in The Lancet Diabetes & Endocrinology. While the gold standard for rare diseases, the very small sample sizes and mostly open-label design are limitations inherent to ultra-rare condition studies.
- Study Age:
- Published in 2020, these are the pivotal trials that led to FDA approval of setmelanotide (IMCIVREE). The drug is now commercially available for these genetic obesity conditions.
- Original Title:
- Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
- Published In:
- The lancet. Diabetes & endocrinology, 8(12), 960-970 (2020)
- Authors:
- Clément, Karine(2), van den Akker, Erica, Argente, Jesús(5), Bahm, Allison, Chung, Wendy K, Connors, Hillori, De Waele, Kathleen, Farooqi, I Sadaf, Gonneau-Lejeune, Julie, Gordon, Gregory, Kohlsdorf, Katja, Poitou, Christine, Puder, Lia, Swain, James, Stewart, Murray, Yuan, Guojun, Wabitsch, Martin, Kühnen, Peter
- Database ID:
- RPEP-04723
Evidence Hierarchy
Frequently Asked Questions
What are POMC and LEPR deficiency and why do they cause severe obesity?
POMC and LEPR are genes involved in your brain's appetite control pathway. When both copies of these genes are mutated, the brain never receives the 'I'm full' signal. People with these deficiencies experience constant, extreme hunger from birth, leading to severe obesity that cannot be controlled by diet or exercise alone.
How does setmelanotide work differently from GLP-1 weight loss drugs?
GLP-1 drugs like semaglutide work by mimicking gut hormones that signal fullness. Setmelanotide activates the MC4 receptor directly in the brain — a downstream switch in the appetite pathway. For patients whose genetic mutations break the upstream signaling, setmelanotide bypasses the broken parts entirely, which GLP-1 drugs cannot do.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-04723APA
Clément, Karine; van den Akker, Erica; Argente, Jesús; Bahm, Allison; Chung, Wendy K; Connors, Hillori; De Waele, Kathleen; Farooqi, I Sadaf; Gonneau-Lejeune, Julie; Gordon, Gregory; Kohlsdorf, Katja; Poitou, Christine; Puder, Lia; Swain, James; Stewart, Murray; Yuan, Guojun; Wabitsch, Martin; Kühnen, Peter. (2020). Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.. The lancet. Diabetes & endocrinology, 8(12), 960-970. https://doi.org/10.1016/S2213-8587(20)30364-8
MLA
Clément, Karine, et al. "Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.." The lancet. Diabetes & endocrinology, 2020. https://doi.org/10.1016/S2213-8587(20)30364-8
RethinkPeptides
RethinkPeptides Research Database. "Efficacy and safety of setmelanotide, an MC4R agonist, in in..." RPEP-04723. Retrieved from https://rethinkpeptides.com/research/clement-2020-efficacy-and-safety-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.